Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04989829
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04985136
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04979390
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04973020
- Locations
- 🇨🇳
Xuanwu Hospital Beijing, Capital Medical University, Beijing, Beijing, China
Extension Study of Hetrombopag in Severe Aplastic Anemia
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT04961710
- Locations
- 🇨🇳
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 444
- Registration Number
- NCT04957550
- Locations
- 🇨🇳
Peking University Hospital, Beijing, Beijing, China
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 780
- Registration Number
- NCT04956432
- Locations
- 🇨🇳
RenJi Hospital, Shanghai JiaoTong University School Of Medicine, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 322
- Registration Number
- NCT04956419
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT04948788
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School, Shanghai, Shanghai, China
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04945616
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
© Copyright 2024. All Rights Reserved by MedPath